Glyoxal in hyperglycaemic ischemic stroke – a cohort study
Authors' conclusion
The glucose-derived α-dicarbonyl glyoxal and glycated amino acids arising from a reaction with glyoxal are associated with a poor outcome in ischemic stroke. Thus, lowering α-dicarbonyls or counteracting their action could be a therapeutic strategy for hyperglycaemic stroke.
Study context
- Population
- Patients with acute stroke
- Participants
- 135 vs 61
- Exposure
- Acute stroke vs Second
- Acute stroken = 135
- Secondn = 61
- Outcome
- Association of serum glyoxal, methylglyoxal and glycated amino acid derivatives (LC-MS/MS) with stroke outcome scales (NIHSS, mRS)
- Follow-up
- 3 months (mRS90)
Methodological detailsvalidation cohort
- Validation cohort
Main finding
As reported in the abstract
Association with bad stroke outcome (mRS90) · 3 months
- Glucose, glyoxal, methylglyoxal and G-H1 positively correlated with bad outcome, in at least one of the two cohorts
- CEL (and pyrraline in one cohort) inversely correlated with stroke outcome, probably reflecting lower food intake in severe stroke
- Poor outcome: higher serum glyoxal and methylglyoxal
Observational data: associations, not effects.
Original publication
Glyoxal in hyperglycaemic ischemic stroke – a cohort study. Cardiovasc Diabetol. Published 12 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →